DEEP DIVES
Rare disease pharma incentives enticing PE: 7 recent deals
SK Capital, Nordic Capital Partners and KKR are among the many PE firms looking at specialty pharma companies developing rare disease treatments.
DAILY INSIGHTS
TECH WATCH
HEALTHCARE
SPECIAL REPORTS
Deals of the Year
Our overall Deal of the Year is Warburg Pincus’ exit of Summit Health (formerly CityMD) at a walloping $8.9bn. Our winners for best deals...
Women in Private Equity
Highlighting the fundraisers, dealmakers and founders who are opening doors for the next generation of women.
Women in Private Equity
Highlighting the fundraisers, dealmakers and founders...
PODCAST
Disruption Matters: The future of due diligence
In this second episode of the third season of the Disruption Matters podcast miniseries, we look at how technology is changing the nature of due diligence and improving investment decisions.
INDUSTRIAL/MANUFACTURING
ENERGY/POWER
VOX POPULI
How to climb through the exit window
Developing a way out for continuation assets continues to be a challenge, writes Dan Ginsberg, managing director, private equity, SGS Maine Pointe.
Why private equity should champion DEI
The spotlight on corporate DEI programs underscores the need to understand the advantages of incorporating DEI into workplace culture, writes Hope Mago, a partner at HCAP.
Realizing liquidity amid market dislocation
The process of exiting an investment is challenging, but the good news it that it can lead to longer holds, writes Patrick Turner, managing director of VSS Capital Partners.